^
    Back
    Association details:
    Biomarker:CXCL10 overexpression + LAMP3 overexpression
    Cancer:Bladder Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Pathol Oncol Res
    Title:

    Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy via interferon-alpha response in muscle-invasive bladder cancer

    Published date:
    04/04/2023
    Excerpt:
    ...we noted the patients who achieved CR or PR were more frequent in CXCL10 high LAMP3 high subgroups…
    DOI:
    https://doi.org/10.3389/pore.2023.1611117